DYN

Dyne Therapeutics, Inc.

Insider Trades

NameValueActionPriceCurrent Price
Cox JohnDirector, Officer: CEO & President
$41k2.7k shares
SellMar 5, 2026
$14.90
--
Kerr DouglasChief Medical Officer
$13k904 shares
SellMar 5, 2026
$14.90
--
Friedl-Naderer JohannaChief Commercial Officer
$2.2k148 shares
SellMar 5, 2026
$14.90
--
Posner Brian SDirector
$45k3k shares
BuyMar 6, 2026
$15.06
--
Kersten DirkDirector
$5.6M281.9k shares
SellMar 10, 2026
$19.80
--
Kersten DirkDirector
$4.2M219.8k shares
SellMar 10, 2026
$19.33
--

News

globenewswire.comDyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comJun 18globenewswire.comDyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.globenewswire.comJun 17globenewswire.comDyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)globenewswire.comJun 3zacks.comDyne Therapeutics Stock Gains 4.5% After BLA Filing for DMD Therapyzacks.comMay 27globenewswire.comDyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)globenewswire.comMay 26